How effective are prolia biosimilars?

Why are companies developing prolia biosimilars?

Companies develop biosimilars to prolia mainly to introduce competition and reduce costs for patients and payers. Prolia (denosumab) is a monoclonal antibody that works by binding RANKL to block osteoclasts, which are bone-resorbing cells. When its patent expired in 2024 in the U.S., multiple manufacturers filed for approval and entered the market. [1]

How does prolia biosimilars effectiveness compare to the original?

Biosimilars must demonstrate no clinically meaningful differences in safety, purity, and potency compared to the original Prolia. The FDA requires extensive analytical studies followed by clinical trials that show similar pharmacokinetics, pharmacodynamics, and efficacy endpoints such as bone mineral density changes and fracture risk reduction. [2]

What side effects are patients asking about with prolia biosimilars?

Patients often raise concerns about osteonecrosis of the jaw, hypocalcemia, and musculoskeletal pain. These risks remain consistent across original and similar versions because the active ingredient is the same. Clinical data show these events occur in 1–2% of patients and occur in the same rates as the original. [3]

When does prolia patent expire and who makes the biosimilars?

The U.S. patent for Prolia expired in 2024. Manufacturers such as Celltrion, Samsung Bioepis, and Sandoz have approved or near-approving biosimilars. [1]

Can biosimilars enter before patent expiry?

Biosimilars can enter before patent expiry through at least-parity pricing or early launch under certain legal conditions. Some companies have obtained approval but delayed launch until patent disputes were settled. [2]

DrugPatentWatch.com